EUVIMEDEUVIMED entdecken
Übersichtsarbeit

URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies

Soumya Mishra, Ranjit K Harwansh, Rupa Mazumder

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01997-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Soumya Mishra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India. Hauptthemen laut MEDLINE: Gout, Organic Anion Transporters, Glucose Transport Proteins, Facilitative, Drug Delivery Systems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 127 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gout is a disorder of metabolism characterized by the deposition of urine crystals, and hyperuricemia, the treatment of which was uricosuric agent and xanthine oxidase inhibitor. Recently, attention has been paid to inhibitors of urate transporters, especially URAT1 and GLUT9, for the possibility of increasing uric acid excretion and decreasing serum uric acid levels in the last few years. The article discusses the physiological functions of URAT1 and GLUT9, genetic associations of these proteins with gout, and novel applications of drug delivery aimed at these proteins. This review comprises of clinical reports, and pharmacology updates regarding urate transporters and transport inhibitors. The role of genetic variants on the functioning of transporters were established and novel drug formulations were examined. The article discusses innovations in drug-delivery systems including sustained-release devices, liposomes, and nanoparticles to circumvent pharmacokinetic limitations and improve therapeutic efficacy. The advent of gene therapy and CRISPR editing for the modification of transporters could also be promising for the treatment of hyperuricemia. The integration of transporter-targeted therapy and new drug delivery systems may dramatically change the landscape of gout treatment in terms of safety and personalized treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutOrganic Anion TransportersGlucose Transport Proteins, FacilitativeDrug Delivery SystemsOrganic Cation Transport ProteinsAnion Transport ProteinsHumansAnimalsHyperuricemiaGenetic TherapyUric AcidGout Suppressants

Stichwörter der Autor:innen

Drug deliveryGoutHyperuricemiaNanoparticlesPrecision medicineUrate transportersUricosuric agents

Substanzen

Organic Anion TransportersGlucose Transport Proteins, FacilitativeOrganic Cation Transport ProteinsSLC22A12 protein, humanSLC2A9 protein, humanUric AcidGout SuppressantsAnion Transport Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India.
  • Department of Pharmacy, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, 201310, India.
  • Department of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India. harwanshranjeet@gmail.com.

Zitieren

APA

Mishra, S., Harwansh, R. K., & Mazumder, R. (2025). URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01997-3

Vancouver

Mishra S, Harwansh RK, Mazumder R. URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01997-3

BibTeX
@article{Mishra2025,
  author = {Mishra, Soumya and Harwansh, Ranjit K and Mazumder, Rupa},
  title = {URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01997-3}
}
Kostenlos starten →